 PARIS and CAMBRIDGE, Mass., Aug. 13, 2021 GLOBE NEWSWIRE -- Biophytis SA NasdaqCM: BPTS, Euronext Growth Paris: ALBPS, Biophytis or the company, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces today that it has performed the obligations imposed on it by i the judgment of the Commercial Court of Paris Tribunal de commerce de Paris of March 16, 2021 and ii the judgment of July 16, 2021 of the Enforcement Judge of the Judicial Court of Paris Juge de lexécution du Tribunal Judiciaire de Paris see press releases of March 19, 2021 and July 19, 2021, available on the Companys website in the case opposing Biophytis to Negma Group Ltd Negma in relation to the ORNANEBSA agreement entered into on August 21, 2019. As part of this performance, Biophytis issued 4,950,000 new shares to Negma, in connection with a capital increase reserved for Negma pursuant to the 13th delegation of the general meeting of May 10, 2021. 